One study has reported that a long-acting GLP1-RA (NLY01) reduced de novo alpha-synuclein aggregation and dopaminergic neuronal loss in the striatum in a transgenic mouse of synucleinopathy, following the intra-striatal delivery of exogenous aggregated alpha-synuclein [81]. The gene discussed is SNCA; the disease is synucleinopathy.